112 related articles for article (PubMed ID: 3076200)
1. Long term bromocriptine treatment in de novo parkinsonian patients.
Herskovits E; Yorio A; Leston J
Medicina (B Aires); 1988; 48(4):345-50. PubMed ID: 3076200
[No Abstract] [Full Text] [Related]
2. The Sydney Multicentre Study of Parkinson's disease: a report on the first 3 years.
Hely MA; Morris JG; Rail D; Reid WG; O'Sullivan DJ; Williamson PM; Genge S; Broe GA
J Neurol Neurosurg Psychiatry; 1989 Mar; 52(3):324-8. PubMed ID: 2647907
[TBL] [Abstract][Full Text] [Related]
3. Bromocriptine: problems with low-dose de novo therapy in Parkinson's disease.
Grimes JD; Delgado MR
Clin Neuropharmacol; 1985; 8(1):73-7. PubMed ID: 3978651
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of administration of low doses of bromocriptine and levodopa in the early treatment of Parkinson disease].
Sternić N; Kostić V
Srp Arh Celok Lek; 1992; 120(1-2):1-5. PubMed ID: 1641693
[TBL] [Abstract][Full Text] [Related]
5. Bromocriptine: long-term low-dose therapy in Parkinson's disease.
Teychenne PF; Bergsrud D; Elton RL; Racy A
Clin Neuropharmacol; 1986; 9(2):138-45. PubMed ID: 3708599
[TBL] [Abstract][Full Text] [Related]
6. [Diurnal worsening in Parkinson patients treated with levodopa].
Piccini P; Del Dotto P; Pardini C; D'Antonio P; Rossi G; Bonuccelli U
Riv Neurol; 1991; 61(6):219-24. PubMed ID: 1813974
[TBL] [Abstract][Full Text] [Related]
7. The Sydney multicentre study of Parkinson's disease. The first 18 months.
Hely MA; Morris JG; Rail D; O'Sullivan DJ; Williamson PM; Genge S; Reid WG; Broe GA
Med J Aust; 1987 Feb; 146(4):195-8. PubMed ID: 3553878
[TBL] [Abstract][Full Text] [Related]
8. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
[TBL] [Abstract][Full Text] [Related]
9. Low-dose bromocriptine in the early phases of Parkinson's disease.
Tolosa E; Blesa R; Bayes A; Forcadell F
Clin Neuropharmacol; 1987 Apr; 10(2):168-74. PubMed ID: 3332610
[TBL] [Abstract][Full Text] [Related]
10. Bromocriptine and lisuride in Parkinson disease.
Lieberman AN; Gopinathan G; Neophytides A; Leibowitz M; Walker R; Hiesiger E
Ann Neurol; 1983 Jan; 13(1):44-7. PubMed ID: 6830164
[TBL] [Abstract][Full Text] [Related]
11. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure.
Nyholm D; Lewander T; Johansson A; Lewitt PA; Lundqvist C; Aquilonius SM
Clin Neuropharmacol; 2008; 31(2):63-73. PubMed ID: 18382177
[TBL] [Abstract][Full Text] [Related]
12. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.
Libman I; Gawel MJ; Riopelle RJ; Bouchard S
Can J Neurol Sci; 1987 Nov; 14(4):576-80. PubMed ID: 3319120
[TBL] [Abstract][Full Text] [Related]
13. A nation-wide collaborative study on the long-term effects of bromocriptine in patients with Parkinson's disease. First interim report in Japan.
Nakanishi T; Mizuno Y; Goto I; Iwata M; Kanazawa I; Kowa H; Mannen T; Nishitani H; Ogawa N; Takahashi A
Eur Neurol; 1988; 28 Suppl 1():3-8. PubMed ID: 3378560
[TBL] [Abstract][Full Text] [Related]
14. Bromocriptine in the treatment of Parkinson's disease: a double-blind study against L-dopa/carbidopa.
Gawel M; Riopelle R; Libman I; Bouchard S
Adv Neurol; 1987; 45():535-8. PubMed ID: 3548263
[No Abstract] [Full Text] [Related]
15. Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment.
Zimmerman TR; Sage JI; Lang AE; Mark MH
Mov Disord; 1994 Mar; 9(2):173-7. PubMed ID: 8196678
[TBL] [Abstract][Full Text] [Related]
16. [Combined therapy of carbidopa and levodopa in Parkinson's disease].
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):201-4. PubMed ID: 4075908
[No Abstract] [Full Text] [Related]
17. A double-blind study of bromocriptine and L-dopa in de novo Parkinson's disease. Short-term results.
Riopelle RJ; Gawel MJ; Libman I; King DB; McLean DR; Paulseth R; Raphy B; Bouchard S
Eur Neurol; 1988; 28 Suppl 1():11-4. PubMed ID: 3288477
[TBL] [Abstract][Full Text] [Related]
18. Use of carbidopa as an adjuvant to levodopa/carbidopa therapy in patients with Parkinson's disease.
Lieberman AN; Gopinathan G; Neophytides A; Pasternack P
N Y State J Med; 1986 Dec; 86(12):655-6. PubMed ID: 3468386
[No Abstract] [Full Text] [Related]
19. [Usefulness of increasing the proportion of carbidopa to levodopa in the long-term treatment of Parkinson's disease].
Bermejo Pareja F; Martínez-Martín P
Med Clin (Barc); 1984 Feb; 82(7):305-10. PubMed ID: 6717135
[No Abstract] [Full Text] [Related]
20. Levodopa-induced regional cerebral blood flow changes in normal volunteers and patients with Parkinson's disease. Lack of correlation with clinical or neuropsychological improvements.
Montastruc JL; Celsis P; Agniel A; Demonet JF; Doyon B; Puel M; Marc-Vergnes JP; Rascol A
Mov Disord; 1987; 2(4):279-89. PubMed ID: 3509776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
